These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27322943)

  • 1. Pioglitazone for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes.
    Ann Intern Med; 2016 Sep; 165(5):. PubMed ID: 27322943
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.
    Bril F; Portillo Sanchez P; Lomonaco R; Orsak B; Hecht J; Tio F; Cusi K
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2950-2961. PubMed ID: 28575232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis.
    Lian J; Fu J
    Front Endocrinol (Lausanne); 2021; 12():615409. PubMed ID: 33995271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pioglitazone on bone mineral density in patients with nonalcoholic steatohepatitis: A 36-month clinical trial.
    Portillo-Sanchez P; Bril F; Lomonaco R; Barb D; Orsak B; Bruder JM; Cusi K
    J Diabetes; 2019 Mar; 11(3):223-231. PubMed ID: 30073778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis.
    Musso G; Cassader M; Paschetta E; Gambino R
    JAMA Intern Med; 2017 May; 177(5):633-640. PubMed ID: 28241279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus-authors' response.
    Rotman Y; Sanyal AJ
    Gut; 2018 Jul; 67(7):1372. PubMed ID: 28468762
    [No Abstract]   [Full Text] [Related]  

  • 10. Pioglitazone for the treatment of NASH in patients with prediabetes or type 2 diabetes mellitus.
    Cusi K
    Gut; 2018 Jul; 67(7):1371. PubMed ID: 28408383
    [No Abstract]   [Full Text] [Related]  

  • 11. [Pathogenetic substantiation of complex treatment of nonalcoholic steatohepatitis and steatosis in patients with pre-diabetes and type 2 diabetes].
    Чопей ІВ; Івачевська ВВ; Чубірко КІ; Гряділь ТІ; Гечко ММ
    Wiad Lek; 2017; 70(2):169-173. PubMed ID: 28511152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis.
    Kawaguchi-Suzuki M; Bril F; Kalavalapalli S; Cusi K; Frye RF
    Aliment Pharmacol Ther; 2017 Jul; 46(1):56-61. PubMed ID: 28470881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Oral Antidiabetic Drugs on Changes in the Liver-to-Spleen Ratio on Computed Tomography and Inflammatory Biomarkers in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease.
    Yabiku K; Mutoh A; Miyagi K; Takasu N
    Clin Ther; 2017 Mar; 39(3):558-566. PubMed ID: 28185715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
    Norris SL; Carson S; Roberts C
    Curr Diabetes Rev; 2007 May; 3(2):127-40. PubMed ID: 18220664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone in nonalcoholic steatohepatitis.
    Targher G
    N Engl J Med; 2007 Mar; 356(10):1067; author reply 1068-9. PubMed ID: 17347462
    [No Abstract]   [Full Text] [Related]  

  • 17. Pioglitazone may reduce cardiovascular events in high risk patients with prediabetes.
    Mayor S
    BMJ; 2016 Feb; 352():i1029. PubMed ID: 26896321
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to pioglitazone in non-alcoholic fatty liver disease patients with
    Wang Z; Du H; Zhao Y; Ren Y; Ma C; Chen H; Li M; Tian J; Xue C; Long G; Xu M; Jiang Y
    Front Endocrinol (Lausanne); 2023; 14():1111430. PubMed ID: 37065735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
    Bray GA; Smith SR; Banerji MA; Tripathy D; Clement SC; Buchanan TA; Henry RR; Kitabchi AE; Mudaliar S; Musi N; Ratner RE; Schwenke DC; Stentz FB; Reaven PD; DeFronzo RA
    Diabetes Obes Metab; 2013 Oct; 15(10):931-7. PubMed ID: 23551856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
    Liao HW; Saver JL; Wu YL; Chen TH; Lee M; Ovbiagele B
    BMJ Open; 2017 Jan; 7(1):e013927. PubMed ID: 28057658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.